RecruitingPhase 4NCT06338293

Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques

Using OFR Software to Observe the Effects of Inclisiran Combined With Statins on the Morphology and Vascular Function of Coronary Vulnerable Plaques


Sponsor

Nanjing First Hospital, Nanjing Medical University

Enrollment

40 participants

Start Date

Mar 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Effects of inclisiran + statins vs. statins on the morphology and vascular function of coronary vulnerable plaques, in order to provide a better treatment and more detailed imaging basis for the treatment of coronary vulnerable plaques.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGInclisiran sodium

The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.

DRUGRosuvastatin

Rosuvastatin


Locations(1)

NanJing Frist Hospital

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06338293


Related Trials